A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for metastatic melanoma

Human Gene Therapy

Volumn 9, Issue 17, 1998, Pages 2585-2594

  Klatzmann, David ^a   Chérin, Patrick ^a   Bensimon, Gilbert ^a   Boyer, Olivier ^a   Coutellier, Anne ^a   Charlotte, Frédéric ^a   Boccaccio, Catherine ^a   Salzmann, Jean Loup ^b   Herson, Serge ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION SITE; MALE; MELANOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; RETROVIRUS; SKIN INFLAMMATION; SKIN METASTASIS; SUICIDE GENE; TRANSGENE; TUMOR NECROSIS; TUMOR VOLUME;

ADULT; AGED; FEMALE; GANCICLOVIR; GENE THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; THYMIDINE KINASE;

DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 2442721450     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349850019427     Document Type: Article

References (28)

1. ANONYMOUS. (1997). Human gene marker/therapy clinical protocols. Hum. Gene Ther. 8, 629-658.
2. BALCH, C.M., HOUGHTON, A.N., and PETERS, L.J. (1993). Cutaneous melanoma. In Cancer Principles and Practice of Oncology, 4th Ed. V.T. DeVita, S. Hellman, and S.A. Rosenberg, eds., pp. 1613-1661.
3. BASTA, M. (1996). Modulation of complement-mediated immune damage by intravenous immune globulin. Clin. Exp. Immunol. 104, 21-25.
4. BASTA, M., and DALAKAS, M.C. (1994). High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729-1735.
5. BI, L.W. (1993). In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4, 725-731.
6. BLAU, H.M., and SPRINGER, M.L. (1995). Gene therapy - a novel form of drug delivery. N. Engl. J. Med. 333, 1204-1207.
7. CARUSO, M., PANIS, Y., GAGANDEEP, S. HOUSSIN, D., SALZMANN, J., and KLATZMANN, D. (1993). Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. U.S.A. 90, 7024-7028.
8. COSSET, F.L., TAKEUCHI, Y., BATTINI, J.L., WEISS, R.A., and COLLINS, M.K. (1995). High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69, 7430-7436.
9. CULVER, K., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E., and BLAESE, R. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
10. DAVIDSON, R.L., KAUFMAN, E.R., CRUMPACKER, C.S., and SCHNIPPER, L.E. (1981). Inhibition of herpes simplex virus transformed and nontransformed cells by acycloguanosine: Mechanisms of uptake and toxicity. Virology 113, 9-19.
11. EZZEDDINE, Z., MARTUZA, R., PLATIKA, D., SHORT, M., MALICK, M., CHOI, A. and BREAKEFIELD, X. (1991). Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3, 608-614.
12. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
13. GAGANDEEP, S., BREW, R., GREEN, B., et al. (1996). Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect." Cancer Gene Ther. 3, 83-88.
14. GAUTREAU, G., KOJIMA, T., WOIMANT, G., CARDOSO, J., DEVILLIER, P., and HOUSSIN, D. (1995). Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection. Transplantation 60, 903-907.
15. HAMEL, W., MAGNELLI, L., CHIARUGI, V.P., and ISRAEL, M.A. (1996). Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 56, 2697-2702.
16. KIANMANESH, A.R., PERRIN, H., PANIS, Y., FABRE, M., NAGY, H.J., HOUSSIN, D., AND KLATZMANN, D. (1997). A "distant" bystander effect of suicide gene therapy: Regression of nontransduced tumors together with a distant transduced tumor. Hum. Gene Ther. 8, 1807-1814.
17. KLATZMANN, D., HERSON, S., CHERIN, P., CHOSIDOW, O., BAILLET, F., BENSIMON, G., BOYER, O., SALZMANN, J.L., and the STUDY GROUP ON GENE THERAPY OF METASTATIC MELANOMA. (1996a). Gene therapy for metastatic malignant melanoma: Evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Hum. Gene Ther. 7, 255-267.
18. KLATZMANN, D., PHILIPPON, J., VALÉRY, C.A., BENSIMON, G., SALZMANN, J.L., and the STUDY GROUP ON GENE THERAPY FOR GLIOBLASTOMA. (1996b). Gene therapy for glioblastoma in adult patients: Safety and efficacy evaluation of an in situ injection of recombinant retroviruses producing cells carrying the thymidine kinase gene of the herpes simplex type 1 virus, to be followed with the administration of ganciclovir. Hum. Gene Ther. 7, 109-126.
19. KLATZMANN, D., VALERY, C.A., BENSIMON, G., MARRO, B., BOYER, O., MOKHTARY, K., DIQUET, B., SALZMANN, J.L., PHILIPPON, J., and the STUDY GROUP ON GENE THERAPY FOR GLIOBLASTOMA. (1998). A phase I/II herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Hum. Gene Ther. 9, 2595-2604.
20. MARSONI, S., HOTH, D., SIMON, R., LEYLAND-JONES, B., DE ROSA, M., and WITTES, R.E. (1987). Clinical drug development: An analysis of phase II trials, 1970-1985. Cancer Treat. Rep. 71, 71-80.
21. MILLER, D., ADAM, M., and MILLER, A. (1990). Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10, 4239-4242.
22. MOOLTEN, F. (1986). Tumor sensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for prospective cancer control strategy. Cancer Res. 46, 5276-5281.
23. MULLIGAN, R. (1993). The basic science of gene therapy. Science 260, 926-932.
24. NISHIYAMA, Y., and RAPP, F. (1979). Anticellular effects of 9-(2-hydroxyethoxymethyl) guanine against herpes simplex virus-transformed cells. J. Gen. Virol. 45, 227-230.
25. SHORT, M.P., CHOI, B.C., LEE, J.K., MALICK, A., BREAKEFIELD, X.O., and MARTUZA, R.L. (1990). Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. 27, 427-439.
26. ST. CLAIR, M.H., LAMBE, C.U., and EURMAN, P.A. (1987). Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob. Agents Chemother. 31, 844-849.
27. TAKEUCHI, Y., PORTER, C.D., STRAHAN, K.M., PREECE, A.F., GUSTAFSSON, K., COSSET, F.L., WEISS, R.A., and COLLINS, M.K. (1996). Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature (London) 379, 85-88.
28. VILE, R.G., NELSON, J.A., CASTLEDEN, S., CHONG, H., and HART, I.R. (1994). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54, 6228-6234.